Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2022-08-04 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Eerste belangrijke stappen in heropbouw van pijplijn en sterke commerciële vooruitgang in H1 2022.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2022 for Galapagos NV. It includes detailed financial statements (income statement, cash position), management commentary on business performance, pipeline updates, and commercial progress. It is not a short announcement (it is over 30,000 characters) and contains substantive financial data, distinguishing it from an Earnings Release (ER) or a Report Publication Announcement (RPA). Therefore, it is classified as an Interim/Quarterly Report. H1 2022
2022-08-04 Dutch
nxr-glpg-h122-en-FINAL-220804-1830.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'report 2022 financial Half-year' and contains comprehensive financial information, including a letter to shareholders, operational reviews, pipeline updates, and condensed consolidated interim financial statements for the first half of 2022. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-04 English
nxr-glpg-h122-nl-FINAL-220804-1830.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Fundamenten & Toekomst verslag 2022 Halfjaar-' (Fundamentals & Future Report 2022 Half-Year) and contains comprehensive financial results, operational updates, and management commentary for the first half of 2022. It includes sections such as 'Financieel resultaat H1 2022' (Financial results H1 2022) and 'Niet-geauditeerde verkorte geconsolideerde tussentijdse cijfers' (Unaudited condensed consolidated interim figures). This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2022
2022-08-04 Dutch
6-K Filing
Regulatory Filings
2022-06-23 English
6-K Filing
Regulatory Filings
2022-06-23 English
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
M&A Activity Classification · 99% confidence The document is a press release dated June 21, 2022, announcing a definitive agreement for Galapagos to acquire CellPoint and AboundBio. It details the strategic rationale, transaction terms (all-cash acquisition), expected benefits, and includes forward-looking statements typical of corporate news. It also announces a webcast presentation for the following day. This type of announcement, detailing a major corporate transaction (M&A), falls under the scope of Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category fits. Since it explicitly details fundraising/acquisition terms, 'CAP' is the most specific fit among the provided options, as it covers financing activities and capital structure changes related to the acquisition funding. It is not a full 10-K, an earnings release (ER), or a proxy statement (DEF 14A/PSI). It is a direct announcement of a transaction, not just a report publication announcement (RPA).
2022-06-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.